Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3191393 | 0.85 | POLB (0.74) | ALDH1A1CYP2D6POLBSMN1; SMN2GAA | |
| SCHEMBL4062604 | 0.84 | ALDH1A1 (1.00) | ALDH1A1CYP2D6POLBGAAKDM4E | |
| SCHEMBL3199394 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2D6POLBSMN1; SMN2GAA | |
| SCHEMBL3182368 | 0.84 | ALDH1A1 (0.70) | ALDH1A1CYP2D6POLBGAAKDM4E | |
| SCHEMBL3196506 | 0.83 | ALDH1A1 (0.70) | ALDH1A1CYP2D6POLBSMN1; SMN2GAA | |
| SCHEMBL3203109 | 0.82 | POLB (0.72) | ALDH1A1CYP2D6POLBSMN1; SMN2MEN1 | |
| SCHEMBL4060347 | 0.81 | ALDH1A1 (0.67) | ALDH1A1CYP2D6POLBCHRM1SMN1; SMN2 | |
| SCHEMBL3205826 | 0.81 | ALDH1A1 (0.70) | ALDH1A1CYP2D6POLBGAAKDM4E | |
| SCHEMBL4129372 | 0.78 | ALDH1A1 (0.70) | ALDH1A1CYP2D6POLBSMN1; SMN2GAA | |
| SCHEMBL4063776 | 0.77 | POLB (0.74) | ALDH1A1CYP2D6POLBSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090149460-A1 | New Compounds | BERG STEFAN | 2009-06-11 | — | — | US | disclosed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149460-A1 | New Compounds | SDHA, CYP11B2, SERPINB1 | ALDH1A1 275/4885CYP2D6 49/4885POLB 1474/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | ALDH1A1 228/4885CYP2D6 20/4885POLB 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.